It is widely accepted that chronic inflammation plays an active role in cancer. Inflammatory immunocytes and related cytokines in the tumor microenvironment are supposed to be a "double-edged sword" in colorectal cancer (CRC) initiation and progression. Interleukin-17 (IL-17), a pleiotropic proinflammatory cytokine, can promote cancer-elicited inflammation and prevent cancer cells from immune surveillance. Despite controversy, IL-17 is generally considered to be a promoter in CRC progression. In this review, we devote to summarize the current progress regarding the role of IL-17 in tumor initiation and progression, as well as the prognostic value in CRC. © 2013 Dang Wu et al.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Wu, D., Wu, P., Huang, Q., Liu, Y., Ye, J., & Huang, J. (2013). Interleukin-17: A promoter in colorectal cancer progression. Clinical and Developmental Immunology. https://doi.org/10.1155/2013/436307